Pharma BD Deal Intelligence
A $9.7B cash acquisition (then the second-largest industrial deal in U.S. history) that gave American Home Products Cyanamid's Lederle Laboratories, its vaccines portfolio, and agricultural chemicals business. The scale bet paid off institutionally, though integrating Cyanamid's sprawling ag-chem and pharma pipeline was no small lift for AHP.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Chemical Bank committed $1.2B to finance the hostile takeover bid, reflecting Wall Street confidence in AHP's ability to extract value from Cyanamid's…
FTC reviews American Home Products Corporation's acquisition of American Cyanamid Company.
American Cyanamid's rise and fall illustrates the risks of conglomerate dismemberment — AHP's $9.5B hostile bid targeted Cyanamid's pharma crown jewels while…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
American Home Products acquired American Cyanamid for approximately $9.7 billion in cash ($95/share), then the second-largest industrial acquisition in U.S. history. The deal gave AHP access to Cyanamid's strong agricultural chemicals and pharmaceutical pipeline, including the Lederle Laboratories division.
$5.5B Global Vaccines Market (mid-1990s)
American Home Products acquired American Cyanamid for $9.7B in 1994, gaining the Lederle Laboratories vaccines division, one of the largest vaccine manufacturers in the US. Lederle produced critical childhood vaccines including Orimune (oral polio) and DTaP vaccines, plus the Centrum multivitamin brand.
The acquisition was the second-largest industrial deal in US history at the time and added Cyanamid's agricultural chemicals business. AHP (later renamed Wyeth) used the combined vaccines platform to develop Prevnar (pneumococcal vaccine), which became one of the best-selling vaccines globally before Pfizer acquired Wyeth in 2009.
American Home Products Corporation completed its acquisition of American Cyanamid Company for $9.7B. American Home Products acquired American Cyanamid for approximately $9.7 billion in cash ($95/share), then the second-largest industrial acquisition in U.S.
Divested non-pharma ops to focus on pharmaceuticals. Part of American Home Products Corporation's $9.7B deal to acquire American Cyanamid Company.
Reflecting pharma focus. Wyeth later sold to Pfizer for $68B in 2009. Part of American Home Products Corporation's $9.7B deal to acquire American Cyanamid Company.
Transformed AHP into Wyeth, commanding $68B from Pfizer in 2009 (7x return). Assessment of American Home Products Corporation's $9.7B acquisition of American Cyanamid Company and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| American Home Products Corporation / American Cyanamid Company (this deal) | 1994 | $9.7B | 83 |
| American Home Products Corporation / BASF AG (Cyanamid agricultural divestiture) | 2000 | $3.8B | 78 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 1994 deals · Oncology deals